PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B

Chronic hepatitis B (CHB) affects 260 million people worldwide. Despite advances in antiviral therapies, functional cure, characterized by sustained loss of hepatitis B surface antigen (HBsAg) and durable viral control after treatment cessation, remains infrequent. The PD-1/PD-L1 immune checkpoint p...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mei Li, Dandan Feng, Juanjuan Shi, Shuangsuo Dang, Xiaoli Jia, Wenjun Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-07-01
Edice:	Frontiers in Immunology
Témata:	chronic hepatitis B functional cure HBsAg HBV immune checkpoint inhibition nucleos(t)ide analogue
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1831739/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!